脂肪酸合成酶促进HER2阳性乳腺癌曲妥珠单抗耐药的研究进展  

Research progress of fatty acid synthase in promoting trastuzumab resistance in HER2-positive breast cancer

作　　者：章杰 徐菁铭 王蓓[2] 徐小宏 ZHANG Jie;XU Jingming;WANG Bei;XU Xiaohong(The First Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou310053,China;Department of Breast Surgery,Zhejiang Provincial Hospital of TCM,Hangzhou310006,China)

机构地区：[1]浙江中医药大学第一临床医学院,浙江杭州310053 [2]浙江省中医院乳腺科,浙江杭州310006

出　　处：《中国现代医生》2020年第12期179-183,共5页China Modern Doctor

基　　金：浙江省实验动物科技计划项目(2018C37133);浙江省中医药科研基金计划项目(2018ZA036)。

摘　　要：约25%~30%乳腺癌为HER2阳性乳腺癌,近年来,虽然抗HER2分子靶向药曲妥珠单抗显著改善HER2阳性乳腺癌的治疗策略和预后,但原发性或继发性曲妥珠单抗耐药越来越受到关注,临床耐药现象亦尚未完全阐明。脂肪酸合成酶(fatty acid synthase,FASN)是内源性脂肪酸从头合成途径的关键酶,FASN过表达与HER2阳性乳腺癌复发和预后密切相关,并在曲妥珠耐药中发挥重要作用,有望成为规避曲妥珠单抗耐药的新靶点,本文就该机制进展作一综述。About 25%-30%of breast cancers are HER2-positive breast cancers.In recent years,although the anti-HER2 molecule targeting drug trastuzumab has significantly improved the treatment strategy and prognosis of HER2-positive breast cancer,primary or secondary trastuzumab resistance has received increasing attention,and clinical resistance has not been fully elucidated.Fatty acid synthase(FASN)is a key enzyme in the de novo synthesis pathway of endogenous fatty acids.FASN overexpression is closely related to the recurrence and prognosis of HER2-positive breast cancer,and plays an important role in trastuzumab resistance.It is expected to become a new target for avoiding trastuzumab resistance.This article reviews the progress of the mechanism.

关 键 词：HER2阳性乳腺癌 脂肪酸合成酶 曲妥珠单抗 耐药机制 

分 类 号：R735.2[医药卫生—肿瘤]